Mpex Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for bacterial diseases. The collaboration provides GSK access to Mpex’s efflux pump inhibitors (EPI) and related technology for use in combination with a variety of antibiotics. The collaboration will focus on drug regimens using Mpex’s EPIs combined with GSK’s development stage compounds as well as existing anti...